Linder et al., 2019 - Google Patents
Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma modelLinder et al., 2019
View HTML- Document ID
- 17283738432612280967
- Author
- Linder B
- Weirauch U
- Ewe A
- Uhmann A
- Seifert V
- Mittelbronn M
- Harter P
- Aigner A
- Kögel D
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Glioblastoma (GBM), WHO grade IV, is the most aggressive primary brain tumor in adults. The median survival time using standard therapy is only 12–15 months with a 5-year survival rate of around 5%. Thus, new and effective treatment modalities are of significant …
- 108020004459 Small Interfering RNA 0 title abstract description 89
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reda El Sayed et al. | MicroRNA therapeutics in cancer: current advances and challenges | |
| Forterre et al. | A comprehensive review of cancer MicroRNA therapeutic delivery strategies | |
| Menon et al. | miRNA: a promising therapeutic target in cancer | |
| Linder et al. | Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma model | |
| Hattinger et al. | Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies | |
| Dang et al. | The role of hypoxia-induced miR-210 in cancer progression | |
| Jhanwar-Uniyal et al. | Glioblastoma: molecular pathways, stem cells and therapeutic targets | |
| Gajda et al. | Combinatory treatment with miR-7-5p and drug-loaded cubosomes effectively impairs cancer cells | |
| Bullock et al. | Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer | |
| Yan et al. | An autocatalytic multicomponent DNAzyme nanomachine for tumor-specific photothermal therapy sensitization in pancreatic cancer | |
| Desantis et al. | MicroRNAs-based nano-strategies as new therapeutic approach in multiple myeloma to overcome disease progression and drug resistance | |
| Serpe et al. | Microglia-derived small extracellular vesicles reduce glioma growth by modifying tumor cell metabolism and enhancing glutamate clearance through miR-124 | |
| Alsidawi et al. | MicroRNAs in brain metastases: potential role as diagnostics and therapeutics | |
| Makowska et al. | microRNAs (miRNAs) in glioblastoma multiforme (GBM)—recent literature review | |
| Li et al. | MicroRNA in human glioma | |
| Grieco et al. | Targeting microRNAs as a therapeutic strategy to reduce oxidative stress in diabetes | |
| Pollutri et al. | TP53/MicroRNA interplay in hepatocellular carcinoma | |
| Titze de Almeida et al. | Delivery of miRNA-targeted oligonucleotides in the rat striatum by magnetofection with Neuromag® | |
| Liu et al. | CX chemokine receptor 7 contributes to survival of KRAS-mutant non-small cell lung cancer upon loss of epidermal growth factor receptor | |
| Li et al. | Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities | |
| Zhang et al. | The miRNA-21-5p payload in exosomes from M2 macrophages drives tumor cell aggression via PTEN/Akt signaling in renal cell carcinoma | |
| Barresi et al. | Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets | |
| Ma et al. | Extracellular vesicles secreted by glioma stem cells are involved in radiation resistance and glioma progression | |
| Wong et al. | Potential miRNAs for miRNA-based therapeutics in breast cancer | |
| Shinde et al. | Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment |